[Form 4] Adaptimmune Therapeutics plc American Insider Trading Activity

Rhea-AI Filing Summary

Adaptimmune insider sale by CFO Gavin Wood: The Form 4 shows that Gavin Wood, Chief Financial Officer and director of Adaptimmune Therapeutics plc (ADAP), sold the equivalent of 96,000 ordinary shares on 09/02/2025. Those shares were represented by 16,000 ADSs, each ADS equal to six ordinary shares, and were sold at $0.0594 per ADS (reported as $0.0099 per ordinary share). After this transaction the reporting person holds 0 ADSs but retains nominal cost and other options covering 11,140,760 ordinary shares of the issuer.

Positive

• Transaction fully disclosed: Form 4 provides required details including dates, quantities, and price.
• Clarification on ADS conversion: Filing explains 1 ADS equals six ordinary shares and shows per-ADS and per-ordinary-share pricing.
• Reporting person retains significant options: Holds options covering 11,140,760 ordinary shares, maintaining continued potential equity exposure.

Negative

• Reporting person now holds 0 ADSs: The filing shows no remaining ADS holdings following the sale.
• Sale reduces direct share ownership: Disposition of 16,000 ADSs (96,000 ordinary shares) decreased immediate insider-held ADS stake.

Insights

Securities Analyst

TL;DR: Company CFO sold 16,000 ADSs (96,000 ordinary shares equivalent) and now holds 0 ADSs but large option positions remain.

This Form 4 records a direct sale by the reporting person on 09/02/2025 of 16,000 ADSs at $0.0594 per ADS, leaving no ADS holdings reported. The disclosure clarifies ADS-to-ordinary share conversion (1 ADS = 6 ordinary shares) and the per-ordinary-share price calculation. Material for investors is the combination of an executed open-market sale and continued exposure via options totaling 11,140,760 ordinary shares, which may affect future dilution or insider alignment depending on option exercise behavior. The filing is a routine Section 16 disclosure and includes an undertaking to provide transaction-level ADS sale details on request.

Corporate Governance Expert

TL;DR: Insider disposition was formally reported; reporting person retains significant option-based interests in the company.

The Form 4 properly identifies the reporting person, relationship to the issuer, transaction date, and the mechanics tying ADSs to ordinary shares. It discloses that post-transaction the reporting person holds no ADSs while retaining options covering 11,140,760 ordinary shares. From a governance standpoint, the filing meets Section 16 transparency requirements and notes the seller will provide granular ADS sale information if requested, which supports record completeness. No amendments or additional contingent arrangements are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wood Gavin

(Last) (First) (Middle)

C/O ADAPTIMMUNE THERAPEUTICS PLC,

60 JUBILEE AVENUE, MILTON PARK

(Street)

ABINGDON X0 OX14 4RX

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptimmune Therapeutics PLC [ ADAP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares with a nominal value of GBP0.001 per share(1)	09/02/2025		S		96,000(2)	D	$0.0099(3)	0(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.

2. The 96,000 ordinary shares reported in Column 4 are represented by 16,000 ADSs.

3. The price reported in Column 4 of $0.0099 per ordinary share is derived from the sale price of $0.0594 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0594. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.

4. The Reporting Person does not hold any ordinary shares in the form of ADSs following this transaction. However, the Reporting Person holds nominal cost options and other options covering an aggregate of 11,140,760 ordinary shares of the Issuer.

	/s/ Gavin Wood	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gavin Wood sell according to the ADAP Form 4?

On 09/02/2025 Gavin Wood sold 16,000 ADSs, which represent 96,000 ordinary shares of Adaptimmune (1 ADS = 6 ordinary shares).

At what price were the ADSs sold in the Form 4?

The ADSs were sold at $0.0594 per ADS, which the filing reports as $0.0099 per ordinary share after dividing by six.

Does the reporting person still hold company equity after the sale?

The reporting person reports holding 0 ADSs following the transaction but retains nominal cost and other options covering 11,140,760 ordinary shares.

What is the reporting person’s role at Adaptimmune?

The Form 4 identifies Gavin Wood as a Director and the company’s Chief Financial Officer.

Will the filer provide additional details about the ADS sales?

Yes. The filing states the reporting person will provide full information regarding the ADSs sold at the reported price upon request to the issuer, security holders, or the SEC staff.